SARS-CoV-2 spike protein mutations: Difference between revisions
Jump to navigation
Jump to search
Eric Martz (talk | contribs) No edit summary |
Eric Martz (talk | contribs) No edit summary |
||
| Line 89: | Line 89: | ||
*January 20, 2021: B.1.1.7 detected in 20 US states<ref name="20states" />. Added L452R lineage<ref name="santaclara" /><ref name="deadline" /><ref name="convalescent" />. | *January 20, 2021: B.1.1.7 detected in 20 US states<ref name="20states" />. Added L452R lineage<ref name="santaclara" /><ref name="deadline" /><ref name="convalescent" />. | ||
*January 25, 2021: Convalescent plasma often ineffective against 501.V2<ref name="wibmer" /> and Moderna developing variant vaccine<ref name="moderna-501.v2" />. | *January 25, 2021: Convalescent plasma often ineffective against 501.V2<ref name="wibmer" /> and Moderna developing variant vaccine<ref name="moderna-501.v2" />. | ||
*January 27, 2021: Mentioned D614G that became prevalent during the onset of the pandemic. See [[#Notes|Note 1]]. Cited definition of ''lineage''<ref name="lineage" />. | *January 27, 2021: Mentioned D614G that became prevalent during the onset of the pandemic. See [[#Notes|Note 1]]. Cited definition of ''lineage''<ref name="lineage" />. Mentioned epidemiological screening utility of deletions H67,V70<ref name="embl1" />. | ||
==See Also== | ==See Also== | ||